BioCentury | Feb 11, 2021
Deals

Next up: Galapagos, Gilead turn to second IPF program, Toledo molecules after $5B deal’s third setback

...By stephen hansen, associate editor A third setback for the $5 billion Galapagos-Gilead deal will now...
...the partners turn their attention to another fibrosis candidate and a Toledo program that targets salt-inducible kinases.Galapagos N.V....
...billion deal that essentially gave Gilead Sciences Inc. (NASDAQ:GILD) ex-EU rights to nearly all of Galapagos’...
BioCentury | Dec 16, 2020
Deals

Third strike for Jyseleca takes therapy out of play in U.S. as focus of Gilead, Galapagos deal shifts to IPF

...after Jyseleca’s surprise setback at FDA, Gilead and Galapagos...
...the August complete response letter for Jyseleca filgotinib from Galapagos N.V....
...and Galapagos valuations for the time being.” Galapagos...
BioCentury | Dec 4, 2020
Product Development

Dec. 3 Quick Takes: Moderna, NIH tout persisting neutralizing antibodies from COVID vaccine; plus Bayer, Galapagos, Braeburn, J&J and Equillium

...gene editing and allogeneic cell therapies across a range of indications.Galapagos hits in IPFGLPG1205 from Galapagos N.V....
...HER1) – Epidermal growth factor receptorGPR84 – G protein-coupled receptor 84 BC Staff Alzumab, itolizumab (EQ001, anti-cd6, t1h) Equillium Biocon Moderna Bayer Galapagos Braeburn Genmab COVID-19 cov19count chs2020 cov19count...
BioCentury | Nov 7, 2020
Deals

Galapagos gains new antifibrotic mechanism through OncoArendi deal

...By Lauren Martz, Senior Editor Galapagos’ latest move to expand its early fibrosis pipeline, via a...
...the company access to a new fibrosis-blocking immune mechanism. Through the exclusive collaboration and licensing agreement, Galapagos N.V....
...million ($343 million) in development, regulatory and commercial milestones and tiered royalties up to low double-digits.Galapagos...
BioCentury | Nov 3, 2020
Product Development

Nov. 2 Quick Takes: EMA reviewing filgotinib and DBV’s peanut allergy therapy; plus Royalty Pharma-CF Foundation, CARSgen, Karyopharm, Aurinia, Regeneron and Astellas

...By BC Staff EMA reviewing filgotinib for ulcerative colitisGilead Sciences Inc. (NASDAQ:GILD) and Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG...
...Pharmaceuticals Inc. Cystic Fibrosis Foundation DBV Technologies S.A. European Medicines Agency (EMA) U.S. Food and Drug Administration (FDA) Gilead Sciences Inc. Galapagos N.V. Karyopharm...
BioCentury | Oct 29, 2020
Product Development

Gilead leaning on cancer deals for growth as filgotinib’s future hangs in the balance

...most notably with ADC developer Immunomedics, for near-term growth. Filgotinib, the centerpiece of an ongoing R&D collaboration with Galapagos N.V. (Euronext:GLPG...
...TACSTD2; EGP-1) – Tumor-associated calcium signal transducer 2 Virginia Li Gilead Sciences Inc. Jyseleca, filgotinib (GLPG0634, GS-6034)Gilead Sciences Inc.Galapagos N.V....
BioCentury | Oct 13, 2020
Product Development

Gilead’s Jyseleca has a leg up over BMS’s Zeposia in biologic-experienced UC patients

...therapies —Jyseleca filgotinib from Gilead and Galapagos...
...are close behind. Partners Gilead Sciences Inc. (NASDAQ:GILD) and Galapagos N.V....
...receptor 1 Stephen Hansen Jyseleca, filgotinib (GLPG0634, GS-6034) Gilead Sciences Inc. Galapagos N.V. Janus...
BioCentury | Sep 29, 2020
Financial News

Sept. 28 Quick Takes: Biogen gains $1.4B on aducanumab update; plus Zai, XtalPi, InventisBio, Galecto, Innovent, Galapagos-Gilead, Biocytogen and ACT Accelerator

...first orders this week. Paul Bonanos Jyseleca, filgotinib (GLPG0634, GS-6034) D-0502 Galapagos N.V. InventisBio...
BioCentury | Sep 12, 2020
Product Development

Galapagos gains on Phase II win for systemic sclerosis candidate

...By Virginia Li, Associate Editor Galapagos’ investors rewarded a clinical win on Friday for ziritaxestat, which...
...Detailed data will be presented at a future medical meeting.The readout is welcome news for Galapagos N.V....
...$1.1 billion in equity up front (see “Filgotinib Setback”; “Europe’s Next Big Biotech”). Despite Friday’s bump, Galapagos’...
BioCentury | Aug 21, 2020
Regulation

Data Bytes: FDA approving new drugs at rapid clip in 2020

...therapies received complete response letters from FDA: filgotinib, a JAK inhibitor from Gilead Sciences Inc. (NASDAQ:GILD) and Galapagos N.V....
Items per page:
1 - 10 of 646
BioCentury | Feb 11, 2021
Deals

Next up: Galapagos, Gilead turn to second IPF program, Toledo molecules after $5B deal’s third setback

...By stephen hansen, associate editor A third setback for the $5 billion Galapagos-Gilead deal will now...
...the partners turn their attention to another fibrosis candidate and a Toledo program that targets salt-inducible kinases.Galapagos N.V....
...billion deal that essentially gave Gilead Sciences Inc. (NASDAQ:GILD) ex-EU rights to nearly all of Galapagos’...
BioCentury | Dec 16, 2020
Deals

Third strike for Jyseleca takes therapy out of play in U.S. as focus of Gilead, Galapagos deal shifts to IPF

...after Jyseleca’s surprise setback at FDA, Gilead and Galapagos...
...the August complete response letter for Jyseleca filgotinib from Galapagos N.V....
...and Galapagos valuations for the time being.” Galapagos...
BioCentury | Dec 4, 2020
Product Development

Dec. 3 Quick Takes: Moderna, NIH tout persisting neutralizing antibodies from COVID vaccine; plus Bayer, Galapagos, Braeburn, J&J and Equillium

...gene editing and allogeneic cell therapies across a range of indications.Galapagos hits in IPFGLPG1205 from Galapagos N.V....
...HER1) – Epidermal growth factor receptorGPR84 – G protein-coupled receptor 84 BC Staff Alzumab, itolizumab (EQ001, anti-cd6, t1h) Equillium Biocon Moderna Bayer Galapagos Braeburn Genmab COVID-19 cov19count chs2020 cov19count...
BioCentury | Nov 7, 2020
Deals

Galapagos gains new antifibrotic mechanism through OncoArendi deal

...By Lauren Martz, Senior Editor Galapagos’ latest move to expand its early fibrosis pipeline, via a...
...the company access to a new fibrosis-blocking immune mechanism. Through the exclusive collaboration and licensing agreement, Galapagos N.V....
...million ($343 million) in development, regulatory and commercial milestones and tiered royalties up to low double-digits.Galapagos...
BioCentury | Nov 3, 2020
Product Development

Nov. 2 Quick Takes: EMA reviewing filgotinib and DBV’s peanut allergy therapy; plus Royalty Pharma-CF Foundation, CARSgen, Karyopharm, Aurinia, Regeneron and Astellas

...By BC Staff EMA reviewing filgotinib for ulcerative colitisGilead Sciences Inc. (NASDAQ:GILD) and Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG...
...Pharmaceuticals Inc. Cystic Fibrosis Foundation DBV Technologies S.A. European Medicines Agency (EMA) U.S. Food and Drug Administration (FDA) Gilead Sciences Inc. Galapagos N.V. Karyopharm...
BioCentury | Oct 29, 2020
Product Development

Gilead leaning on cancer deals for growth as filgotinib’s future hangs in the balance

...most notably with ADC developer Immunomedics, for near-term growth. Filgotinib, the centerpiece of an ongoing R&D collaboration with Galapagos N.V. (Euronext:GLPG...
...TACSTD2; EGP-1) – Tumor-associated calcium signal transducer 2 Virginia Li Gilead Sciences Inc. Jyseleca, filgotinib (GLPG0634, GS-6034)Gilead Sciences Inc.Galapagos N.V....
BioCentury | Oct 13, 2020
Product Development

Gilead’s Jyseleca has a leg up over BMS’s Zeposia in biologic-experienced UC patients

...therapies —Jyseleca filgotinib from Gilead and Galapagos...
...are close behind. Partners Gilead Sciences Inc. (NASDAQ:GILD) and Galapagos N.V....
...receptor 1 Stephen Hansen Jyseleca, filgotinib (GLPG0634, GS-6034) Gilead Sciences Inc. Galapagos N.V. Janus...
BioCentury | Sep 29, 2020
Financial News

Sept. 28 Quick Takes: Biogen gains $1.4B on aducanumab update; plus Zai, XtalPi, InventisBio, Galecto, Innovent, Galapagos-Gilead, Biocytogen and ACT Accelerator

...first orders this week. Paul Bonanos Jyseleca, filgotinib (GLPG0634, GS-6034) D-0502 Galapagos N.V. InventisBio...
BioCentury | Sep 12, 2020
Product Development

Galapagos gains on Phase II win for systemic sclerosis candidate

...By Virginia Li, Associate Editor Galapagos’ investors rewarded a clinical win on Friday for ziritaxestat, which...
...Detailed data will be presented at a future medical meeting.The readout is welcome news for Galapagos N.V....
...$1.1 billion in equity up front (see “Filgotinib Setback”; “Europe’s Next Big Biotech”). Despite Friday’s bump, Galapagos’...
BioCentury | Aug 21, 2020
Regulation

Data Bytes: FDA approving new drugs at rapid clip in 2020

...therapies received complete response letters from FDA: filgotinib, a JAK inhibitor from Gilead Sciences Inc. (NASDAQ:GILD) and Galapagos N.V....
Items per page:
1 - 10 of 646